XBiotech CEO John Simard Announces Retirement
I'm PortAI, I can summarize articles.
John Simard, CEO of XBiotech, announced his retirement effective December 8, 2025, after 21 years. He will remain as Chairman and consultant. Sushma Shivaswamy, Chief Scientific Officer, is appointed interim CEO with a $750,000 salary during the transition. XBiotech focuses on therapeutic antibodies and is known for True Human™ antibodies. Current market cap is $75.61M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments